Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSThe biggest oncology meeting of the year has an accidental theme: peptides are powering at least three new drug classes landing at the same time. A map of who's there and what they showed.
A new analysis covering 54,680 transplant recipients found those on GLP-1 drugs were about half as likely to die. Heart problems dropped by about the same amount. The first clear picture for a high-risk population.
Two new research papers tested whether AI can design drug molecules. General-purpose chatbot-style AIs collapse on specific targets. A specialized tool built for one narrow peptide job found 76 working candidates where the broad approach found zero.
A new retail floor and a new capital ceiling for the weight-loss drug market, landed in the same week. The price patients pay and the price investors pay, both just reset.
Tirzepatide produced 22% weight loss vs 15% for semaglutide in a head-to-head trial. The bigger number wins the weight race but comes with a bigger muscle cost. A third hormone may fix it.
A late-stage substudy showed semaglutide lowering an Alzheimer's biological marker in spinal fluid. The same week, a peer-reviewed review mapped three peptide classes already in Alzheimer's trials.
Microsoft researchers pulled every lab-tested AI drug design result into one scorecard. Binders work. Antibodies are inconsistent. Enzymes are harder. One target keeps beating the AI.
New real-world data suggests tirzepatide loses more muscle than semaglutide at matched weight reduction. The next generation of drugs is adding a glucagon receptor to protect muscle.
Svetlana Mojsov identified the active form of GLP-1 in 1983. Every Ozempic, Wegovy, Mounjaro, and Zepbound traces back to her work. Public credit took forty years to catch up.
Orforglipron is the first pill in the Ozempic class. In a two-year diabetes trial of 2,749 adults, it cut deaths by more than half compared to standard insulin therapy.
Twelve peptides came off a restricted list. Seven more, including BPC-157 and TB-500, are going to a July committee vote. Most outlets reported these as one decision. They are not.